ArticleJournal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent2008
Focus on ziprasidone: a review of its use in child and adolescent psychiatry.
Article in Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Antipsychotics-Loaded Nanometric Emulsions for Brain Delivery.Pharmaceutics · 2022Review
- The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.CNS drugs · 2014Review
- Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Paediatric drugs · 2013Review
- Evidence review and clinical guidance for the use of ziprasidone in Canada.Annals of general psychiatry · 2013Article
- Review of the safety of second-generation antipsychotics: are they really "atypically" safe for youth and adults?The primary care companion for CNS disorders · 2012Article
- Review
- Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study.Child and adolescent psychiatry and mental health · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review published literature regarding ziprasidone in child and adolescent psychiatry.
methodsA literature review was conducted using the medline search term: 'ziprasidone' with limits: Human trials, English language, All Child (Age 0-18). Additional articles were identified from reference information and poster presentation data.
resultsTwo randomized controlled trials and five prospective open-label studies have been conducted with ziprasidone. Additionally, several case reports and case series are reviewed. Ziprasidone has a greater propensity for QT(c) prolongation and risk for fatal arrhythmias compared to other atypical antipsychotics. Careful history taking regarding presence of congenital long QT syndrome is essential. Given limited clinical experience, electrocardiogram monitoring at baseline and following attainment of ziprasidone target dosage is warranted. No deaths from overdose have been reported in children and adolescents. Ziprasidone has a low potential for extrapyramidal side effects. Prolactin changes are small and transient. Lethargy, drowsiness, agitation and tachycardia were the most common adverse effects in randomized trials. Body weight changes with ziprasidone were comparable to placebo-treated subjects.
conclusionAt present, ziprasidone should be considered a second or third-line option for a limited set of conditions. A role may exist for ziprasidone in patients who have experienced significant metabolic adverse effects with other atypical antipsychotics.
Indexed as
Identifiers
19018327PMC2583921W1514037618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.